Professional Bio
David Haas, MD, is Professor of Medicine in the Division of Infectious Diseases within the Department of Medicine at Vanderbilt University Medical Center. He is also a Professor of Pharmacology, Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine, and Adjunct Professor of Internal Medicine at Meharry Medical College. He is also a board-certified infectious diseases specialist.
As an accomplished HIV clinical trialist and leader in human pharmacogenomic research relevant to HIV infection and its therapy, Dr. Haas has led the design and implementation of many HIV clinical trials since the early 1990s. In recent years his work has expanded to include pharmacogenomics of anti-tuberculosis therapy.
He established and has led the AIDS Clinical Trials Group (ACTG) Clinical Research Site at Vanderbilt since its inception. He has led the ACTG's pharmacogenomics program since 2000, and championed the establishment of the ACTG's Human DNA Repository. His work with the ACTG led to the seminal observation that a frequent CYP2B6 polymorphism predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent. He is co-PI of a substantial, multidisciplinary R01 entitled "Pharmacogenomics of HIV Therapy."
Dr. Haas is highly engaged in multidisciplinary research with an emphasis on the importance of human genomics for antiretroviral and anti-tuberculosis drug disposition, efficacy, and toxicity. He is also associate director of the Tennessee Center for AIDS Research.
Relevant Links
Publications
Education
MD - Vanderbilt University, 1983
Residency - Medicine - Vanderbilt University, 1987
Fellowship - Infectious Diseases - Vanderbilt University, 1991
Contact
Email
Kimryn.Rathmell@Vumc.Org
Address
777 Preston Research Building
2220 Pierce Ave
Nashville, TN 37232-6307